Knewton Kazunori Sakata, MD | |
700 Ne 87th Ave, Vancouver, WA 98664-1913 | |
(360) 882-2778 | |
(360) 604-1727 |
Full Name | Knewton Kazunori Sakata |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 14 Years |
Location | 700 Ne 87th Ave, Vancouver, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1538484746 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | MD60631195 (Washington) | Primary |
207RC0200X | Internal Medicine - Critical Care Medicine | MD60631195 (Washington) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
Legacy Salmon Creek Medical Center | Vancouver, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Legacy Salmon Creek Hospital | 0446295711 | 223 |
The Vancouver Clinic Inc Ps | 3173436490 | 471 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Monitoring participants' biological clocks may be the quickest way to determine the effectiveness of experimental drugs currently under development to treat Angelman syndrome: a debilitating genetic disorder that occurs in more than one in every 15,000 live births.
According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."
The U.S. Food and Drug Administration today announced an action regarding the implementation of the Family Smoking Prevention and Tobacco Control Act. The Agency has officially established the Tobacco Products Scientific Advisory Committee (TPSAC).
› Verified 2 days ago
Entity Name | The Vancouver Clinic Inc Ps |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1992759427 PECOS PAC ID: 3173436490 Enrollment ID: O20031111000793 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Monitoring participants' biological clocks may be the quickest way to determine the effectiveness of experimental drugs currently under development to treat Angelman syndrome: a debilitating genetic disorder that occurs in more than one in every 15,000 live births.
According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."
The U.S. Food and Drug Administration today announced an action regarding the implementation of the Family Smoking Prevention and Tobacco Control Act. The Agency has officially established the Tobacco Products Scientific Advisory Committee (TPSAC).
› Verified 2 days ago
Entity Name | Legacy Salmon Creek Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356357784 PECOS PAC ID: 0446295711 Enrollment ID: O20051223000194 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Monitoring participants' biological clocks may be the quickest way to determine the effectiveness of experimental drugs currently under development to treat Angelman syndrome: a debilitating genetic disorder that occurs in more than one in every 15,000 live births.
According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."
The U.S. Food and Drug Administration today announced an action regarding the implementation of the Family Smoking Prevention and Tobacco Control Act. The Agency has officially established the Tobacco Products Scientific Advisory Committee (TPSAC).
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Knewton Kazunori Sakata, MD Po Box 873010, Vancouver, WA 98687-3010 Ph: (360) 882-2778 | Knewton Kazunori Sakata, MD 700 Ne 87th Ave, Vancouver, WA 98664-1913 Ph: (360) 882-2778 |
News Archive
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
Monitoring participants' biological clocks may be the quickest way to determine the effectiveness of experimental drugs currently under development to treat Angelman syndrome: a debilitating genetic disorder that occurs in more than one in every 15,000 live births.
According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."
The U.S. Food and Drug Administration today announced an action regarding the implementation of the Family Smoking Prevention and Tobacco Control Act. The Agency has officially established the Tobacco Products Scientific Advisory Committee (TPSAC).
› Verified 2 days ago
Kanuboddu Nagarjuna Reddy, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave Ste 220, Vancouver, WA 98664 Phone: 360-882-2778 | |
Dr. David Steiger, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 505 Ne 87th Ave Ste 301, Vancouver, WA 98664 Phone: 360-514-7374 Fax: 360-514-7384 | |
Phillip M Cullison Bonner, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2211 Ne 139th St, Vancouver, WA 98686 Phone: 360-487-1000 | |
Louise M Schultz, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave, Vancouver, WA 98664 Phone: 360-882-2778 | |
Marissa Krienke, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 700 Ne 87th Ave Ste And240, Vancouver, WA 98664 Phone: 360-882-2778 | |
Joel David Mclarry, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave, Suite 210, Vancouver, WA 98664 Phone: 360-882-2778 | |
Dr. Samuel Everett George, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 19005 Se 34th St Bldg 3, Vancouver, WA 98683 Phone: 360-726-6720 Fax: 360-726-6729 |